Gunderson Dettmer represented client Remix Therapeutics, a clinical-stage biotechnology company, in its $60 million financing. Remix Therapeutics is leveraging the power of data analytics and machine learning, to develop novel small molecule therapies designed to reprogram RNA processing and treat diseases. The new capital will support clinical development of the company's lead program, REM-422, and further advance the pipeline of RNA processing targeted therapeutics.

In the announcement of the transaction, Co-founder and CEO Peter Smith, Ph.D. said, "We are proud of and encouraged by the support of such a strong syndicate of investors who believe in Remix's ability to develop novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. This financing enables us to continue development of our pipeline and advance our lead program, REM-422, into the clinic for the treatment of adenoid cystic carcinoma and acute myeloid leukemia/myelodysplastic syndromes this year."

The Gunderson Dettmer deal team was led by Tim Ehrlich and included Jen Lichtman and Ali Blum.

Companies
Remix Therapeutics